Hot Features
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 a... Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.29 | -14.0776699029 | 2.06 | 2.09 | 1.68 | 59876 | 1.8518262 | DR |
| 4 | -0.04 | -2.20994475138 | 1.81 | 2.1447 | 1.535 | 49330 | 1.83699612 | DR |
| 12 | -0.15 | -7.8125 | 1.92 | 2.2359 | 1.45 | 44921 | 1.74448519 | DR |
| 26 | -0.72 | -28.9156626506 | 2.49 | 2.77 | 1.35 | 68437 | 1.78649369 | DR |
| 52 | 0.43 | 32.0895522388 | 1.34 | 3.855 | 0.8288 | 115315 | 2.1100752 | DR |
| 156 | 0.02 | 1.14285714286 | 1.75 | 3.855 | 0.42 | 263823 | 1.23159668 | DR |
| 260 | -16.79 | -90.463362069 | 18.56 | 27.92 | 0.42 | 238265 | 3.11750653 | DR |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.